journal article·2024-10-09

Bufalin CaCO3 Nanoparticles Triggered Pyroptosis through Calcium Overload via Na+/Ca2+ Exchanger Reverse for Cancer Immunotherapy

Tingxuan Li, Yitong Zhang, Hanyue Li, Hanjie Zhang, Juntao Xie, Zimu Li, Kai Zhang, Yongkang Yu, Lin Mei

Nano Letters· Volume 24· Issue 40
Publisher page

Abstract

Bufalin is a promising active ingredient in traditional Chinese medicine but has shown limited anticancer applications due to its toxicity. Here, we report BCNPs@gel, a bufalin-containing CaCO 3 nanoparticle hydrogel, for enhancing cancer treatment through inducing cellular pyroptosis. Under the tumor microenvironment’s low pH conditions, bufalin and Ca 2+ are released from the delivery system. Bufalin serves as a direct anticancer drug and a Na + /K + -ATPase inhibitor by forcing the Na + /Ca 2+ exchanger to reverse its function, which transfers Ca 2+ into cytoplasm and ultimately causes Ca 2+ overload-triggered pyroptosis. Meanwhile, we found that bufalin can upregulate PD-L1 in tumor cells. In combination with the PD-1 antibody, the delivery system showed a greater performance during the cancer treatment. BCNPs@gel enhances antitumor efficiency, reduces systemic side effects, extends antitumor mechanism of bufalin, and provides new strategies for inducing pyroptosis and calcium overload in cancer immunotherapy via Na + /K + -ATPase inhibitor. This work provides an application model for numerous other traditional Chinese medicine ingredients.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · Cell death mechanisms and regulation · Toxoplasma gondii Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, P. R. China

School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, Singapore, 637371, Singapore

Funding

Science Fund for Distinguished Young Scholars of Tianjin Municipality · National Natural Science Foundation of China · Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences · Science and Technology Program of Tianjin City (the Basic Research Cooperation Special Foundation of Beijing-Tianjin-Hebei Region) · the Fundamental Research Funds for the Central Universities

References (41)

Show source-provided references
1. 10.1158/1535-7163.MCT-17-129610.1158/1535-7163.MCT-17-1296 ↗
2. 10.1016/j.phrs.2022.10644210.1016/j.phrs.2022.106442 ↗
3. 10.1186/s12935-019-0806-110.1186/s12935-019-0806-1 ↗
4. 10.1038/s41586-024-07403-210.1038/s41586-024-07403-2 ↗
5. 10.1007/s10565-019-09462-y10.1007/s10565-019-09462-y ↗
6. 10.1016/j.phrs.2021.10572810.1016/j.phrs.2021.105728 ↗
7. 10.3892/ijmm.2020.474510.3892/ijmm.2020.4745 ↗
8. 10.3389/fphar.2023.127433610.3389/fphar.2023.1274336 ↗
9. 10.3390/molecules2719658610.3390/molecules27196586 ↗
10. 10.1055/a-1248-262610.1055/a-1248-2626 ↗
11. 10.2147/IJN.S31315310.2147/IJN.S313153 ↗
12. 10.1016/j.ejphar.2020.17337910.1016/j.ejphar.2020.173379 ↗
13. 10.3389/fonc.2019.0157210.3389/fonc.2019.01572 ↗
14. 10.2147/OTT.S11028110.2147/OTT.S110281 ↗
15. 10.3390/ijms2307400710.3390/ijms23074007 ↗
16. 10.1073/pnas.142299711210.1073/pnas.1422997112 ↗
17. 10.1038/nrd268210.1038/nrd2682 ↗
18. 10.1111/j.1582-4934.2009.00708.x10.1111/j.1582-4934.2009.00708.x ↗
19. 10.1248/bpb.33.74310.1248/bpb.33.743 ↗
20. 10.3390/molecules2805223110.3390/molecules28052231 ↗
21. 10.1038/s41586-020-2079-110.1038/s41586-020-2079-1 ↗
22. 10.1038/s41586-020-2071-910.1038/s41586-020-2071-9 ↗
23. 10.1038/s41565-022-01125-010.1038/s41565-022-01125-0 ↗
24. 10.1016/j.drup.2023.10100510.1016/j.drup.2023.101005 ↗
25. 10.3390/ijms2012301710.3390/ijms20123017 ↗
26. 10.1016/j.apsb.2016.11.00110.1016/j.apsb.2016.11.001 ↗
27. 10.1159/00049264510.1159/000492645 ↗
28. 10.3892/ijo.2019.469610.3892/ijo.2019.4696 ↗
29. 10.1016/j.chempr.2019.06.00310.1016/j.chempr.2019.06.003 ↗
30. 10.1002/adfm.20200850710.1002/adfm.202008507 ↗
31. 10.1002/anie.20220490410.1002/anie.202204904 ↗
32. 10.1146/annurev.pathol.1.110304.10021810.1146/annurev.pathol.1.110304.100218 ↗
33. 10.1196/annals.1387.04410.1196/annals.1387.044 ↗
34. 10.1161/01.RES.0000181170.87738.f310.1161/01.RES.0000181170.87738.f3 ↗
35. 10.1016/j.vph.2004.03.00510.1016/j.vph.2004.03.005 ↗
36. 10.1152/ajpheart.00007.200710.1152/ajpheart.00007.2007 ↗
37. 10.1186/s12935-023-03196-y10.1186/s12935-023-03196-y ↗
38. 10.1002/adma.20170370210.1002/adma.201703702 ↗
39. 10.1038/nature2239310.1038/nature22393 ↗
40. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
41. 10.1038/s41423-018-0054-710.1038/s41423-018-0054-7 ↗